MolecularMD is acquired by ICON
2019年2月22日 - 12:00AM
MolecularMD Corporation, a molecular
diagnostic specialty laboratory that enables the development and
commercialisation of precision medicines in oncology, announced
today that it has been acquired by ICON plc (NASDAQ: ICLR).
MolecularMD’s extensive scientific and clinical biomarker
experience expands ICON’s capabilities in molecular diagnostic
testing and also adds expanded testing platforms, including
next-generation sequencing and immunohistochemistry, to ICON’s
laboratory service offering. MolecularMD’s specialty central
laboratory offering and associated client base extends ICON’s reach
into the support of precision medicine programs across all phases
of drug – diagnostic co-development.
Founded in Dublin, Ireland in 1990, ICON is a global provider of
drug development solutions and services to the pharmaceutical,
biotechnology and medical device industries. In support of its
global clinical development programs, ICON operates a global
network of fully accredited laboratory facilities, including
Central Laboratories in Dublin, Ireland, Farmingdale NY, Singapore
and Tianjin, China. ICON also has a Bioanalytical Laboratory in
Whitesboro, NY.
The acquisition by ICON provides MolecularMD’s client base
access to a comprehensive range of services offered globally to
support drug development programs. For over a decade, MolecularMD
has built capabilities and experience in drug-diagnostic
co-development and is highly respected within the industry and with
regulatory agencies.
“We remain committed to providing agile clinical trial assay
development across technology platforms and extending all the way
through regulatory approval and commercialisation of companion
diagnostics,” commented Dan Snyder, President, MolecularMD. “The
integration with ICON’s full spectrum of drug development services
across all therapeutic areas and global reach will be recognised as
very high value to our pharmaceutical and biotechnology
clients.”
Dr. Steve Cutler, Chief Executive Officer, ICON plc, said: “We
are committed to expanding the testing we offer into specialised
areas so that we can help customers to maximize the value of
laboratory data to accelerate timelines and reduce development
costs. MolecularMD enhances our laboratory offering in molecular
diagnostic testing, a key area in oncology research, and brings to
ICON expanded testing platforms and diagnostic services.
MolecularMD is a recognised leader in the analytical development
and clinical validation of molecular diagnostic assays and we are
delighted to welcome their team of experts to
ICON.”
About MolecularMD
MolecularMD Corporation is a diagnostics company that enables
the development and commercialisation of precision medicines in
oncology. Its tests are designed to allow appropriate selection,
monitoring and management of patients treated with
molecularly-targeted and immuno-oncology cancer therapies.
MolecularMD integrates gold standard and innovative platform
technologies with custom clinical assay design and validation to
accelerate all phases of clinical development, including FDA
approval and commercialisation of in vitro companion diagnostic
tests for novel anti-cancer agents. MolecularMD is the exclusive
manufacturer of the MRDx® BCR-ABL Test. For more information please
visit www.molecularmd.com and www.mrdxtest.com.
About ICON plc
ICON plc is a global provider of outsourced drug development and
commercialisation solutions and services to the pharmaceutical,
biotechnology, medical device and government and public health
organisations. The company specialises in the strategic
development, management and analysis of programs that support
clinical development - from compound selection to Phase I-IV
clinical studies. With headquarters in Dublin, Ireland, ICON
currently, operates from 89 locations in 37 countries and has
approximately 13,670 employees.
Further information is available at www.iconplc.com
Media Inquiries:
Lucinda Sandon-AllumWeber
Shandwick LSandon-Allum@webershandwick.comT +44 (0)20 7067
0548
ICON (NASDAQ:ICLR)
過去 株価チャート
から 6 2024 まで 7 2024
ICON (NASDAQ:ICLR)
過去 株価チャート
から 7 2023 まで 7 2024